Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1979 2
1980 2
1981 8
1982 3
1983 5
1984 5
1985 2
1986 3
1987 7
1988 5
1989 6
1990 9
1991 10
1992 10
1993 12
1994 13
1995 11
1996 13
1997 16
1998 15
1999 16
2000 16
2001 10
2002 21
2003 20
2004 24
2005 29
2006 23
2007 22
2008 19
2009 19
2010 24
2011 24
2012 32
2013 43
2014 45
2015 56
2016 49
2017 64
2018 83
2019 100
2020 118
2021 117
2022 131
2023 122
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

1,256 results

Results by year

Filters applied: . Clear all
Page 1
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.
Belvarafenib induced ARAF mutant dimers, and dimers containing mutant ARAF were active in the presence of inhibitor. ...Together, our findings reveal specific and compensatory functions for the ARAF isoform and implicate ARAF mutations as a driver of r …
Belvarafenib induced ARAF mutant dimers, and dimers containing mutant ARAF were active in the presence of inhibitor. ...Togeth …
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.
Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, Merna Timaul N, Hechtman J, Paroder V, Lin M, Mattar M, Qiu J, Chang Q, Zhao H, Zhang J, Little M, Adachi Y, Han SW, Taylor BS, Ebi H, Abdel-Wahab O, de Stanchina E, Rudin CM, Jänne PA, McCormick F, Yao Z, Rosen N. Su W, et al. Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. doi: 10.1016/j.molcel.2022.04.034. Epub 2022 May 24. Mol Cell. 2022. PMID: 35613620 Free PMC article.
RAF protein kinases are effectors of the GTP-bound form of small guanosine triphosphatase RAS and function by phosphorylating MEK. We showed here that the expression of ARAF activated RAS in a kinase-independent manner. Binding of ARAF to RAS displaced the GTPase-ac …
RAF protein kinases are effectors of the GTP-bound form of small guanosine triphosphatase RAS and function by phosphorylating MEK. We showed …
ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers.
Mooz J, Riegel K, Ps H, Sadanandam A, Marini F, Klein M, Werner U, Roth W, Wilken-Schmitz A, Tegeder I, Rajalingam K. Mooz J, et al. Sci Adv. 2022 Mar 18;8(11):eabk1538. doi: 10.1126/sciadv.abk1538. Epub 2022 Mar 18. Sci Adv. 2022. PMID: 35302851 Free PMC article.
RAF kinases are highly conserved serine/threonine kinases, and among the three RAF isoforms (ARAF, BRAF, and CRAF), the pathophysiological relevance of ARAF is not well defined. ...ARAF suppressed the promoter activity of ERBB3, and reconstitution of ARAF …
RAF kinases are highly conserved serine/threonine kinases, and among the three RAF isoforms (ARAF, BRAF, and CRAF), the pathophysiolo …
ARAF Mutations Limit Response to RAF Dimer Inhibition.
[No authors listed] [No authors listed] Cancer Discov. 2021 Jul;11(7):1610. doi: 10.1158/2159-8290.CD-RW2021-069. Epub 2021 May 14. Cancer Discov. 2021. PMID: 33990346
Belvarafenib is active in BRAF- and NRAS-mutant tumors, but acquired ARAF mutations drive resistance....
Belvarafenib is active in BRAF- and NRAS-mutant tumors, but acquired ARAF mutations drive resistance....
Silencing ARAF Suppresses the Malignant Phenotypes of Gallbladder Cancer Cells.
Lin W, Tong C, Zhang W, Cen W, Wang Y, Li J, Zhu Z, Yu J, Lu B. Lin W, et al. Biomed Res Int. 2020 Aug 18;2020:3235786. doi: 10.1155/2020/3235786. eCollection 2020. Biomed Res Int. 2020. PMID: 32923479 Free PMC article.
As the most common biliary tract tumor, gallbladder cancer (GBC) seriously harms human health while the function of ARAF in GBC remains elusive. Here, we found that ARAF expression was upregulated in gallbladder cancer tissues. ...Moreover, knocking down ARAF …
As the most common biliary tract tumor, gallbladder cancer (GBC) seriously harms human health while the function of ARAF in GBC remai …
CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
Venkatanarayan A, Liang J, Yen I, Shanahan F, Haley B, Phu L, Verschueren E, Hinkle TB, Kan D, Segal E, Long JE, Lima T, Liau NPD, Sudhamsu J, Li J, Klijn C, Piskol R, Junttila MR, Shaw AS, Merchant M, Chang MT, Kirkpatrick DS, Malek S. Venkatanarayan A, et al. Cell Rep. 2022 Feb 8;38(6):110351. doi: 10.1016/j.celrep.2022.110351. Cell Rep. 2022. PMID: 35139374 Free article.
Quantitative proteomics demonstrates increased levels of CRAF:ARAF dimers in KRAS mutant cells, and depletion of both CRAF and ARAF rescues the CRAF-loss phenotype. ...
Quantitative proteomics demonstrates increased levels of CRAF:ARAF dimers in KRAS mutant cells, and depletion of both CRAF and ARA …
Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R, Guo Y, Han L, Feng S, Cao J, Sun Y, Cao Z, Cui X. Liu R, et al. Clin Exp Med. 2023 Dec;23(8):5269-5279. doi: 10.1007/s10238-023-01134-w. Epub 2023 Aug 12. Clin Exp Med. 2023. PMID: 37572153
However, the occurrence of ARAF-positive LCH cases is extremely rare, with only two reported globally. ...It was considered an ARAF hotspot mutation. All reported ARAF-positive patients worldwide exhibited characteristic pathological features of LCH, albeit w …
However, the occurrence of ARAF-positive LCH cases is extremely rare, with only two reported globally. ...It was considered an ARA …
Spatial regulation of ARAF controls the MST2-Hippo pathway.
Rauch J, Kolch W. Rauch J, et al. Small GTPases. 2019 Jul;10(4):243-248. doi: 10.1080/21541248.2017.1288686. Epub 2017 Mar 10. Small GTPases. 2019. PMID: 28281933 Free PMC article.
In our recent study, we showed that the ARAF-MST2 complex is regulated by subcellular compartmentalization during epithelial differentiation. ...In contrast, non-malignant squamous epithelia have ARAF localized at the plasma membrane, where the control of MST2-media …
In our recent study, we showed that the ARAF-MST2 complex is regulated by subcellular compartmentalization during epithelial differen …
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.
Li D, March ME, Gutierrez-Uzquiza A, Kao C, Seiler C, Pinto E, Matsuoka LS, Battig MR, Bhoj EJ, Wenger TL, Tian L, Robinson N, Wang T, Liu Y, Weinstein BM, Swift M, Jung HM, Kaminski CN, Chiavacci R, Perkins JA, Levine MA, Sleiman PMA, Hicks PJ, Strausbaugh JT, Belasco JB, Dori Y, Hakonarson H. Li D, et al. Nat Med. 2019 Jul;25(7):1116-1122. doi: 10.1038/s41591-019-0479-2. Epub 2019 Jul 1. Nat Med. 2019. PMID: 31263281
Identifying the causal genes will allow for developing affordable therapies in keeping with precision medicine implementation(2). Here we identified a recurrent gain-of-function ARAF mutation (c.640T>C:p.S214P) in a 12-year-old boy with advanced anomalous lymphatic dise …
Identifying the causal genes will allow for developing affordable therapies in keeping with precision medicine implementation(2). Here we id …
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP, Marais R. Rebocho AP, et al. Oncogene. 2013 Jun 27;32(26):3207-12. doi: 10.1038/onc.2012.330. Epub 2012 Aug 27. Oncogene. 2013. PMID: 22926515
Here, we investigated the role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors. ...We further show that ARAF binds to and is activated by BRAF and that …
Here, we investigated the role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activat …
1,256 results